Effects of CB3717 on Myeloid Leukaemia in Rats
Author Information
Author(s): A.A.M. Ermens, J. Lindemans, J. Abels
Primary Institution: Institute of Hematology, Erasmus University
Hypothesis
The study investigates the chemotherapeutic activity of the antifolate CB3717 in a rat model of myeloid leukaemia.
Conclusion
CB3717 showed limited antileukaemic effects compared to 5-fluorouracil, likely due to its slower action and rapid clearance from the body.
Supporting Evidence
- CB3717 did not show significant antileukaemic effects at lower doses.
- 5-FU demonstrated a remarkable antileukaemic effect with no signs of toxicity.
- High doses of CB3717 resulted in severe weight loss and increased water consumption in rats.
Takeaway
The study tested a new cancer drug called CB3717 on sick rats, but it didn't work as well as another drug called 5-FU.
Methodology
Rats with leukaemia were treated with different doses of CB3717 and 5-FU, and their health was monitored by measuring liver and spleen weights and blood cell counts.
Limitations
The study's findings may not directly translate to human treatments due to differences in drug metabolism and effects in humans.
Participant Demographics
Rats were used as the model organism for the study.
Want to read the original?
Access the complete publication on the publisher's website